Company intelligence / Profile preview

Micro CRISPR

Ownership: Private
Employees: ~100
Development stage: Phase 1

Overview

Completed animal trials for MyCART (CAR T-cell therapy) and received approval for human trials. Currently enrolling patients for Phase 1 clinical trials, expected to complete in 12 months with commercial launch anticipated in 12-24 months (as of March 2025).

Therapeutic areas: OncologyHematology
Modalities: Cell therapyGene therapyCAR T-cell therapy
Industry: Biotech

Drug pipeline

7 assets

MicroLesterol

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Cancer hospitals across India for clinical trials

Beyond the preview

Go deeper on Micro CRISPR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micro CRISPR.

Explore the full profile